Clinical Trial Update: Effects of Atomoxetine in Mild Cognitive Impairment [Phase 2]

View source ↗

Summary

Phase 2 trial update on atomoxetine for mild cognitive impairment has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment

Drugs mentioned

• Atomoxetine (Atomoxetine)

Snippet

Sponsor: Emory University | Conditions: Mild Cognitive Impairment | Phase 2 | Status: COMPLETED | Results posted: 2018-12-05